AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3755554 — intervention group
Group type: COMPARATOR
Intervention: Inza 200 mg and 400 mg tablets
Number of subjects: 18
Study 31805385 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative fascia iliaca block (35-40 mL ropivacaine 0.35%)
Number of subjects: 60
Study 31805385 — intervention group
Group type: COMPARATOR
Intervention: Control (no fascia iliaca block)
Number of subjects: 60
Study 31390801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive-enriched food combinations (specific combinations not detailed)
Number of subjects: 167
Study 28483183 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at the thoracolumbar sympathetic ganglions
Number of subjects: 75
Study 28483183 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at acupuncture points
Number of subjects: 75
Study 28483183 — intervention group
Group type: COMPARATOR
Intervention: Control group (mid-calf area stimulation)
Number of subjects: 75
Study 25927539 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH-IT (Competent Adulthood Transition with Cognitive Behavioral Humanistic and Interpersonal Training)
Number of subjects: 234
Study 25927539 — intervention group
Group type: COMPARATOR
Intervention: General health education Internet intervention
Number of subjects: 234
Study 23169797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-tensor imaging (DT) at 3T
Number of subjects: 40
Study 21854279 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-risk reduction intervention
Number of subjects: 515
Study 21854279 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-inflated negative binomial (ZINB) model
Number of subjects: 515
Study 21854279 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative binomial (NB) model
Number of subjects: 515
Study 21854279 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-inflated Poisson (ZIP) model
Number of subjects: 515
Study 21854279 — intervention group
Group type: EXPERIMENTAL
Intervention: Poisson hurdle (PH) model
Number of subjects: 515
Study 21854279 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative binomial hurdle (NBH) model
Number of subjects: 515
Study 19369319 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (1 to 4 mg/day)
Number of subjects: 498
Study 19369319 — intervention group
Group type: EXPERIMENTAL
Intervention: amisulpride (200 to 800 mg/day)
Number of subjects: 498
Study 19369319 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine (5 to 20 mg/day)
Number of subjects: 498
Study 19369319 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine (200 to 750 mg/day)
Number of subjects: 498
Study 19369319 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone (40 to 160 mg/day)
Number of subjects: 498
Study 19369319 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 498
Study 16330155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) training
Number of subjects: 28
Study 16330155 — intervention group
Group type: COMPARATOR
Intervention: Waiting control condition
Number of subjects: 28
Study 15253956 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (Sustanon 100)
Number of subjects: 10
Study 15253956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11849859 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day, n = 82)
Number of subjects: 246
Study 11849859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day, n = 83)
Number of subjects: 246
Study 11849859 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet alone, n = 81)
Number of subjects: 246
Study 9688105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg once daily)
Number of subjects: 226
Study 9688105 — intervention group
Group type: COMPARATOR
Intervention: Dexfenfluramine (15 mg twice daily)
Number of subjects: 226
Study 9688105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 226
Study 7526440 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 60
Study 7526440 — intervention group
Group type: EXPERIMENTAL
Intervention: co-trimoxazole
Number of subjects: 60
Study 7526440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 60
Study 2690972 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 176
Study 2690972 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA)
Number of subjects: 176
Study 4574642 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 67
Study 4574642 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 67
Study 4574642 — intervention group
Group type: COMPARATOR
Intervention: Tepid sponging alone
Number of subjects: 67
Study 4574642 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol with tepid sponging
Number of subjects: 67
Study 30138237 — intervention group
Group type: EXPERIMENTAL
Intervention: CMJ AS (Countermovement Jump with Arm Swing)
Number of subjects: 22
Study 30138237 — intervention group
Group type: COMPARATOR
Intervention: CMJ NAS (Countermovement Jump without Arm Swing)
Number of subjects: 22
Study 31557258 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking on sand
Number of subjects: 59
Study 31557258 — intervention group
Group type: COMPARATOR
Intervention: Walking on stable ground
Number of subjects: 59
Study 28004319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower depressive symptoms
Number of subjects: 178
Study 28004319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower HIV-related stigma
Number of subjects: 178
Study 28004319 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher social support
Number of subjects: 178
Study 28004319 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical functioning
Number of subjects: 178
Study 28004319 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher general health perceptions
Number of subjects: 178
Study 26275751 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-AIG thickness measured using echocardiography
Number of subjects: 311
Study 26275751 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-RV thickness measured using echocardiography
Number of subjects: 311
Study 26275751 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-AIG thickness for predicting CAD
Number of subjects: 311
Study 23371755 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 30
Study 23371755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21762493 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhizhu pills containing immature orange fruit of Citrus aurantium L. (IFCA), 6 g each time, 3 times a day for 4 weeks
Number of subjects: 160
Study 21762493 — intervention group
Group type: COMPARATOR
Intervention: Zhizhu pills containing immature orange fruit of Citrus sinensis Osbeck (IFCS), 6 g each time, 3 times a day for 4 weeks
Number of subjects: 160
Study 19339139 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-tailored training (CTT) model
Number of subjects: 0
Study 19339139 — intervention group
Group type: COMPARATOR
Intervention: Standard 2-day MI workshop
Number of subjects: 0
Study 19339139 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors with more formal education
Number of subjects: 0
Study 19339139 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors with less endorsement of a disease model of addiction
Number of subjects: 0
Study 19339139 — intervention group
Group type: EXPERIMENTAL
Intervention: Agencies with counselors viewing their organization as more open to change
Number of subjects: 0
Study 19339139 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining activities supporting ongoing learning and implementation of MI
Number of subjects: 0
Study 16728696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab-containing conditioning regimen and autologous stem cell transplantation (auto-SCT)
Number of subjects: 7
Study 15302014 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive hospital discharge planning and close follow-up at a HF clinic
Number of subjects: 338
Study 15302014 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study 11027879 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation-induced hyper intensity area (RIHA) in glioma patients
Number of subjects: 9
Study 11027879 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal appearing white matter (NAWM) in glioma patients
Number of subjects: 9
Study 11027879 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of NAA and Cr between RIHA and NAWM in glioma patients
Number of subjects: 9
Study 8646223 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 24
Study 1502484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg tablets three times daily for 4 weeks
Number of subjects: 120
Study 1502484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6497518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide therapy (2 weeks)
Number of subjects: 20
Study 6497518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide therapy (4 weeks)
Number of subjects: 20
Study 6497518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30767964 — intervention group
Group type: EXPERIMENTAL
Intervention: Group dynamics-based exercise
Number of subjects: 26
Study 30767964 — intervention group
Group type: COMPARATOR
Intervention: Personal training
Number of subjects: 26
Study 28968031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy + ozone therapy (subgroup 1a: intravenous ozonized physiological solution, n=28)
Number of subjects: 139
Study 28968031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy + ozone therapy (subgroup 1b: major ozonized autohemotherapy, n=29)
Number of subjects: 139
Study 28968031 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment including gravitational therapy + medical ozone (subgroup 2a: standard medical therapy + ozonized physiological solution + gravitational therapy, n=31)
Number of subjects: 139
Study 28968031 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment including gravitational therapy + medical ozone (subgroup 2b: standard medical therapy + major ozonized autohemotherapy + gravitational therapy, n=31)
Number of subjects: 139
Study 28968031 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy only (control group, n=20)
Number of subjects: 139
Study 26269002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg or 30 mg)
Number of subjects: 120
Study 26269002 — intervention group
Group type: COMPARATOR
Intervention: Control (no pioglitazone)
Number of subjects: 120
Study 23466754 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus incentives (MI+)
Number of subjects: 0
Study 23466754 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 0
Study 21070297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 246
Study 21070297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 21070297 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine and Placebo
Number of subjects: 246
Study 19855170 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 6/11/16/18 vaccine
Number of subjects: 2617
Study 19855170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2617
Study 16267842 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil 150 mg/day
Number of subjects: 425
Study 16267842 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine 25 mg/day
Number of subjects: 425
Study 14720615 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg drospirenone/30 microg ethinylestradiol
Number of subjects: 0
Study 14720615 — intervention group
Group type: COMPARATOR
Intervention: 150 microg levonogestrel/30 microg ethinylestradiol
Number of subjects: 0
Study 10866253 — intervention group
Group type: EXPERIMENTAL
Intervention: First Access for Shock and Trauma (FAST)
Number of subjects: 31
Study 10866253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Injection Gun
Number of subjects: 31
Study 10866253 — intervention group
Group type: EXPERIMENTAL
Intervention: SurFast
Number of subjects: 31
Study 10866253 — intervention group
Group type: EXPERIMENTAL
Intervention: Jamshidi needle
Number of subjects: 31
Study 9114758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 205
Study 9114758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 1423365 — intervention group
Group type: EXPERIMENTAL
Intervention: K-strophanthidin
Number of subjects: 20
Study 1423365 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 20
Study 1423365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 4045435 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-micrograms recombinant hepatitis B vaccine
Number of subjects: 110
Study 4045435 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-micrograms recombinant hepatitis B vaccine
Number of subjects: 110
Study 4045435 — intervention group
Group type: COMPARATOR
Intervention: plasma-derived hepatitis B vaccine (5-micrograms)
Number of subjects: 110
Study 4045435 — intervention group
Group type: COMPARATOR
Intervention: plasma-derived hepatitis B vaccine (10-micrograms)
Number of subjects: 110
Study 2956867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoximone at a maximum cumulative dose of 3.0 mg/kg
Number of subjects: 118
Study 2956867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoximone at a maximum cumulative dose of 10.5 mg/kg
Number of subjects: 118
Study 2956867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoximone
Number of subjects: 118
Study 2956867 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of intravenous enoximone
Number of subjects: 118
Study 29288102 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser (PSAL)
Number of subjects: 30
Study 29288102 — intervention group
Group type: COMPARATOR
Intervention: Q-switched alexandrite laser (QSAL)
Number of subjects: 30
Study 27979912 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision in the right atrium joining the lateral tunnel suture line and the tricuspid valve annulus
Number of subjects: 134
Study 27979912 — intervention group
Group type: COMPARATOR
Intervention: No incision (Control)
Number of subjects: 134
Study 25768800 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Number of subjects: 133
Study 25768800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 133
Study 25768800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 23174090 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (1000 mg/d)
Number of subjects: 26
Study 23174090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19909980 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2216684
Number of subjects: 269
Study 19909980 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 269
Study 19909980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 18403765 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with emboli-protection device
Number of subjects: 334
Study 18403765 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 334
Study 16649875 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-based vouchers
Number of subjects: 90
Study 16649875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 90
Study 16649875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of abstinence-based vouchers and cognitive-behavioral therapy
Number of subjects: 90
Study 12732601 — intervention group
Group type: EXPERIMENTAL
Intervention: Acolysis (therapeutic ultrasound)
Number of subjects: 181
Study 12732601 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 181
Study 10819856 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (30 microg/min continuous subcutaneous infusion)
Number of subjects: 513
Study 10819856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 513
Study 10819856 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 513
Study 10819856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study 10819856 — intervention group
Group type: COMPARATOR
Intervention: Atosiban and Placebo
Number of subjects: 513
Study 8625548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Number of subjects: 373
Study 1340743 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (C + HCTZ)
Number of subjects: 55
Study 1340743 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (CT)
Number of subjects: 55
Study 6437467 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg SSHA
Number of subjects: 440
Study 6437467 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg SSHA
Number of subjects: 440
Study 6437467 — intervention group
Group type: COMPARATOR
Intervention: 5000 units sodium heparin
Number of subjects: 440
Study 6437467 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 440
Study 31427224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based group intervention (4 sessions, 2-3 months post-surgery)
Number of subjects: 259
Study 31427224 — intervention group
Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 259
Study 30178515 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided tacrolimus dosing
Number of subjects: 53
Study 30178515 — intervention group
Group type: COMPARATOR
Intervention: Standard tacrolimus dosing
Number of subjects: 53
Study 27553581 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol infusion (5 μg/kg/min during general anesthesia)
Number of subjects: 50
Study 27553581 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (no landiolol)
Number of subjects: 50
Study 27553581 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol infusion
Number of subjects: 50
Study 24554512 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OC) containing ethynyloestradiol and cyproterone acetate (EE‐CPA) for 4 months
Number of subjects: 42
Study 24554512 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET) 850 mg bid for 4 months
Number of subjects: 42
Study 24554512 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) or EE‐CPA for 4 months
Number of subjects: 42
Study 22936190 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication robot
Number of subjects: 34
Study 22936190 — intervention group
Group type: COMPARATOR
Intervention: Control robot
Number of subjects: 34
Study 20937655 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Newborn Care (ENC) training
Number of subjects: 1096
Study 20937655 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Resuscitation Program (NRP) training
Number of subjects: 1096
Study 20937655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 1096
Study 18664053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulvodynia (vestibulodynia and generalized vulvodynia)
Number of subjects: 246
Study 18664053 — intervention group
Group type: COMPARATOR
Intervention: Candida vulvovaginitis
Number of subjects: 246
Study 16038682 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM)
Number of subjects: 14
Study 16038682 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric analyses of the ACC
Number of subjects: 14
Study 16038682 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic maps of the labels of the pregenual ACC
Number of subjects: 14
Study 16038682 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 14
Study 11775762 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stent placement
Number of subjects: 10000000
Study 11775762 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 10000000
Study 11775762 — intervention group
Group type: COMPARATOR
Intervention: Surgical bypass
Number of subjects: 10000000
Study 15321222 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L Ringer's solution preload administered over 10 min before spinal anaesthesia
Number of subjects: 40
Study 15321222 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 40
Study 15321222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received prophylactic infusion of ephedrine (60 mg in Ringer's solution 1000 ml) after spinal anaesthesia
Number of subjects: 40
Study 7923256 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day terazosin
Number of subjects: 12
Study 7923256 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day terazosin
Number of subjects: 12
Study 7923256 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day terazosin
Number of subjects: 12
Study 7923256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3136963 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg three times daily for the first six postoperative weeks
Number of subjects: 193
Study 3136963 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 193
Study 31249332 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based exergaming (EXER group)
Number of subjects: 52
Study 31249332 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise (CE group)
Number of subjects: 52
Study 27620962 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood crime safety
Number of subjects: 238
Study 27620962 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood crime safety in low fear of falling group
Number of subjects: 238